戻る Agenda
Session 5: Risk Minimisation Measures
Session Chair(s)
Raghda Mohamed
Patient Safety & Pharmacovigilance Cluster Lead - West Gulf, East Gulf and Leva, Takeda, United Arab Emirates
The primary goal of a Risk Minimization Plan (RMiP) is to develop activities that help patients and health care providers understand an important known or potential risk associated with a drug and to lessen the chance that a serious side effect might occur. This session will share good practices across MENA region and present examples from EU-RMP creation.
Speaker(s)
Raghda Mohamed
Patient Safety & Pharmacovigilance Cluster Lead - West Gulf, East Gulf and Leva, Takeda, United Arab Emirates
Risk Minimization Activities
Hadir Rostom
Head, Egyptian Pharmaceutical Vigilance Center (EPVC), Pharmaceutical Affairs Central Administration (CAPA), Ministry of Health, Egypt, Egypt
Challenges and good practices from other regions
Mohamed Abdillahi
Risk Management Product Lead, Pfizer, United Kingdom
Risk Minimisation Plan in EU